I. MODIFIED AGREEMENTS | |||
Company* |
Company* |
Change from original agreement | Terms/Details (Date) |
| |||
Enzo Biochem |
Digene Corp. (DIGE) |
Entered a settlement and license agreement related to an Enzo patent on nucleic acid detection |
The settlement involves payments to Enzo of $30.5M and the granting to Digene of a nonexclusive, royalty-bearing, worldwide license for use of the '581 family of patents (10/14) |
ComGenex |
Echelon Biosciences Inc.* |
Echelon got rights to acquire ComGenex's share of intellectual property from their drug discovery collaboration |
Echelon can secure exclusive rights to joint IP by making up-front and milestone payments; they also will explore additional discovery programs in cancer (10/25) |
Immunomedics |
Cytogen Corp. (CYTO) and C.R. Bard Inc. |
They settled a patent suit that claimed Cytogen's ProstaScint infringed an Immunomedics patent |
The settlement included an undisclosed payment to Immunomedics with no admission of fault or liability (9/29) |
MonoGen Inc.* |
Molecular Diagnostics Inc. (OTC BB:MCDG) |
MDI subsidiary AccuMed International Inc. and MonoGen settled a license dispute on technologies for monitoring and diagnosing cancer |
As part of the settlement, AccuMed assigned to MonoGen all the AccuMed patents and know-how covering the subject; MDI got a nonexclusive license covering some of its products that use fluorescent probes (10/18) |
Seattle |
Genentech Inc. (NYSE:DNA) |
Genentech is designating additional antigen targets under their collaboration on antibody-drug conjugates |
Seattle Genetics gets a $1.6M access fee and remains eligible for milestone and royalty payments (11/9) |
XOMA Ltd. |
Millennium Pharmaceuticals Inc. (MLNM) |
They restructured November 2001 deal for development of MLN2222, which is in Phase I trials for coronary artery bypass graft surgery |
XOMA opted to work under a milestone and royalty arrangement rather than sharing costs and profits; XOMA will be responsible for work through Phase I, instead of Phase II; Millennium's stock purchase obligations ended (10/12) |
II. TERMINATED AGREEMENTS | |||
Xenova |
Millennium Pharmaceuticals Inc. (MLNM) |
Millennium will stop funding the XR5944/XR11576 program in cancer after completion of ongoing Phase I trials |
Millennium has been the North American partner on the program since 2001, and paid $11.5M up front in the deal; Xenova will decide the program's future after Phase I data are in (11/16) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. |